3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer
Reuters
Aug 28
<a href="https://laohu8.com/S/01244">3D Medicines</a> Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer
3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.